Atlas Trials

Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.

Clinical trial NCT03769194 · COMPLETED

Trial details

NCT number
NCT03769194
Sponsor
Pfizer
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Lyme Borreliosis
Start date
2018-12-17
Primary completion
2019-12-18
Enrollment
572

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.